PMLA case: Lalu's daughter Misa Bharti, husband granted bail

Agencies
March 5, 2018

New Delhi, Mar 5: A special court here today granted bail to RJD chief Lalu Prasad's daughter Misa Bharti and her husband in a money laundering case.

Special Judge Arvind Kumar granted the relief to Bharti and her husband Shailesh Kumar, who appeared before the court in pursuance to summons issued against them, on a personal bond of Rs two lakh with a surety of a like amount each and directed them not to leave the country without prior permission of the court.

The two had moved bail applications. During the hearing, the Enforcement Directorate (ED) opposed the bail plea of the accused, saying they indulged in a "very serious" economic offence.

"Persons on such a post are committing such kind of activities which are totally against the nation," ED counsel Atul Tripathi said.

The court asked if the probe agency had arrested the couple during the case investigation to which the ED replied in the negative.

This prompted the court to ask ED, "Why do you now want the court to take them in custody?"

The court had on February 8 issued summonses against Bharti, her husband and her firm Mishail Packers and Printers as accused in the case after taking cognizance of the charge sheet filed by the ED.

The ED had on December 23 filed its final report against Bharti and her husband Shailesh Kumar.

The agency had earlier attached a Delhi farmhouse of the couple in connection with its money-laundering probe.

The farmhouse, located at 26, Palam Farms in south Delhi's Bijwasan area, was attached provisionally under the Prevention of Money Laundering Act (PMLA).

It belonged to Bharti and Kumar and was "held in the name of M/s Mishail Packers and Printers Private Limited", the central probe agency had said.

"It was purchased in 2008-09, using Rs 1.2 crore involved in money laundering," it had alleged.

The agency had raided the farmhouse and a few other locations in July last year as part of its probe against two brothers -- Surendra Kumar Jain and Virendra Jain -- and others, who were alleged to have laundered several crores of rupees using shell companies.

The Jain brothers, currently on bail, were arrested by the ED under the PMLA.

The ED had also arrested Rajesh Agrawal, a chartered accountant who had allegedly mediated and provided a cash amount of "Rs 90 lakh to the Jain brothers in advance so as to invest in M/s Mishail Packers and Printers Pvt Ltd as share premium".

One of the firms that the arrested duo dealt with was Mishail Printers and Packers Pvt Ltd, according to the ED.

Bharti and her husband are alleged to have been directors in this firm in the past.

"The company, M/s Mishail Packers and Printers, was registered at 25, Tughlak Road, New Delhi till the shares were bought by Bharti.

"It was only during 2009-10 that the address was changed to Farm no. 26, Palam Farms, VPO Bijwasan, New Delhi. Bharti and Kumar were the directors of the company during the relevant period," the ED had said.

The ED had alleged that the Jain brothers, Agrawal and the daughter and son-in-law of the former Bihar chief minister were the "key persons behind the laundering of Rs 1.2 crore".

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 25,2020

New Delhi, Jul 25: India reported a spike of 48,916 coronavirus cases on Saturday, according to the Union Ministry of Health and Family Welfare.

The total COVID-19 positive cases stand at 13,36,861 including 4,56,071 active cases, 8,49,431 cured/discharged/migrated. With 757 deaths in the last 24 hours, the cumulative toll reached 31,358.

Maharashtra has reported 3,57,117 coronavirus cases, the highest among states and Union Territories in the country.

A total of 1,99,749 cases have been reported from Tamil Nadu till now, while Delhi has recorded a total of 1,28,389 coronavirus cases.

According to the Indian Council of Medical Research (ICMR), 4,20,898 samples were tested for coronavirus on Friday and overall 1,58,49,068 samples have been tested so far.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 19,2020

Shirdi, Jan 19: Shirdi in Maharashtra will remain closed for an indefinite period from today in the wake of state Chief Minister Uddhav Thackeray's decision to develop Pathri town in Parbhani district as Sai Baba's birthplace.

However, Deepak Madukar Muglikar, Chief Executive Officer of Shri Saibaba Sansthan Trust, has said that Sai Baba Temple in Shirdi will remain open today and will not be impacted by the closure of the city.

"There are some reports in media that Sai Temple in Shirdi will remain closed on January 19. I want to clarify that it is just a rumor. Temple will remain open on January 19," Mr Muglikar said.

A call has been given for indefinite closure of Shirdi after Mr Thackeray's reported comment terming Pathri in Parbhani as Sai Baba's birthplace.

"Devotees will not face any difficulty if they come to Shirdi," said B Wakchaure, member of Saibaba Sansthan Trust.

Uddhav Thackeray has recently announced that Pathri will be developed as the birthplace of Sai Baba for religious tourism and also took a review meeting of the development plans in the Parbhani district.

One of the most popular religious destinations in the country, Saibaba Temple in Shirdi witnesses lakh of devotees visiting the holy site every year.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 25,2020

New Delhi, Jun 25: After the Drug Controller General of India (DCGI) given its approval to manufacture and market the generic version of COVID-19 drug Remdesivir, COVIFOR, Hyderabad-based drugmaker Hetero Limited has delivered the first set of 20,000 vials in two equal lots of 10,000 each across 5 states.

The first batch, which is being marketed under the brand name of COVIFOR, was delivered to Maharashtra, Delhi, Gujarat Tamil Nadu and Hyderabad. Hetero has set a target to produce one lakh vials of the drug in two-three weeks.

The other lot would be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week to meet the emergency requirements.

Managing director of Hetero Healthcare M Srinivasa Reddy said “the launch of Covifor in the country is a milestone in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital thereby reducing the increasing pressure on the medical infrastructure overburdened ue to accelerating COVID-19 infection rates," he said as reported by news agency.

"We are closely working with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country”, Reddy said.

Covifor is a generic brand of Remdesivir which is used for the treatment of COVID-19 in adults and children hospitalised with strong symptoms of the disease. The Health Ministry had, on June 13, recommended the use of anti-viral drug Remdesivir in moderate stage of COVID-19.

Dr Reddys Laboratories and Hetero are among others which have separately entered into non-exclusive licensing agreements with the original drug-maker Gilead Sciences Inc to register, make and sell the investigational drug Remdesivir in India and other countries.

Remdesivir would be made in the company's formulation facility in Hyderabad, which has been approved by global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, Hetero had earlier said.

The treatment first showed improvement in trials on coronavirus patients and was approved for emergency use in severely ill patients in the United States and South Korea.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.